introduction

Xiaokun Zhang,Ph.D.

  发布时间: 2016-09-08   信息员:    浏览次数: 46

Xiao-kun Zhang,  Ph.D.

Professor,  Dean


Experience

Dr. Zhang received his bachelor  degree from Xiamen University in China and earned his Ph.D. in Biochemistry from  the University of Vermont in the United States. He spent three years as a  postdoctoral fellow at Sanford-Burnham Medical Research Institute prior to his  appointment to the faculty in 1992, and currently he is the professor at the  cancer center of Sanford-Burnham Medical Research Institute. In 2006, he was  recruited to Xiamen University as Dean of the school of pharmaceutical science.  He was awarded as “Cheung Kong Scholar Lecture Professor” and was elected to the  “National Thousand Talents Program”. Dr. Zhang has published more than 100  papers in prestigious journals such asScience,NatureandCell, and holds more than ten U.S.  patents.


Research

Dr. Zhang studies the  chemopreventive and therapeutic effects of Vitamin A and its synthetic analogs  in various cancers and other diseases. He discovered a new vitamin A signaling  pathway through RXR protein complexes. An agent that modulates RXR activities  has been approved by the FDA for treating lymphoma patients and is now in phase  III clinical trial for lung cancer. Dr. Zhang also found that a gene that binds  Vitamin A (called RARb) acts as a tumor suppressor. His group recently  discovered a new paradigm for destroying cancer cells using a protein called  TR3, or Nur77. TR3 is often present at high levels in cancer cells to promote  their growth in the nucleus. Dr. Zhang recently showed that he is able to move  TR3 from the nucleus to the mitochondria. In mitochondria, TR3 binds to Bcl-2, a  protein that maintains tumor growth. The binding converts Bcl-2 from a tumor  protector to a tumor destroyer. He also defined the oncogenic function of a  truncated RXRa (tRXRa), which is specifically expressed in cancer cells and  promotes cancer cell growth by activation of PI3K. Based on that, he developed a  lead compound which targets tRXRa and inhibits tumor growth. Dr. Zhang's  laboratory is now exploring the possibility of treating cancer patients using a  class of specific agents that induce TR3 migration and modulate  tRXRa.


Team

Daxiong  HanAssociateprofessor

Ph. DXiamen University,  China

Guanghui  Wangassistant professor

Ph. DShenyang Pharmaceutical University,  China

Yang  Xuassistant  professor

Ph. D  TheUniversityof Hong kong

Quancheng  Chenassistant  professor

Ph. DChungnam National University,  Korea


Selected Publications:last 5 years

1.Kolluri, S. K, Zhu, X, Zhou, X, Lin, B, Chen,  Y,Sun, K, Tian, X,Town, J, Cao, X, Lin, F, Zhai, D, Kitada, S, Luciano,  F,O'Donnell, E, Cao, Y, He, F,Lin, J, Reed, J. C, Satterth wait, A.  C,Zhang, X. K, A short Nur77-derived peptide  converts Bcl-2 from aprotector to a killer.Cancer Cell2008,14 (4), 285-98.

2.Zhou H, Liu W, Su Y, Wei Z, Liu J, Kolluri SK,  Wu H, Cao Y, Chen J, Wu Y, Yan T, Cao X, Gao W, Molotkov A, Jiang F, Li WG, Lin  B, Zhang HP, Yu J, Luo SP, Zeng JZ, Duester G, Huang PQ,Zhang XK. NSAID sulindac and its analog bind  RXRalpha and inhibit RXRalpha-dependent AKT signaling.Cancer Cell2010, 17(6):560-573.

3.Sun, Z,Cao, X,Jiang, M. M, Qiu, Y, Zhou, H ,  Chen, L, Qin, B, Wu, H, Jiang, F,

Chen, J, Liu, J  ,Dai, Y, Chen, H. F, Hu, Q. Y, Wu, Z, Zeng, J. Z, Yao, X. S, Zhang, X. K.,Inhibition of beta-catenin  signaling by nongenomic action of orphan nuclear receptor  Nur77.Oncogene2012,31 (21), 2653-67.

4.Yan, T. D, Wu, H, Zhang, H. P, Lu, N, Ye, P,  Yu, F. H, Zhou, H, Li, W. G, Cao, X, Lin, Y. Y, He, J. Y, Gao, W. W, Zhao, Y, Xie, L, Chen, J. B,Zhang, X. K, Zeng, J. Z.,Oncogenic potential  of retinoic acid receptor-gamma in hepatocellular carcinoma.Cancer Res2010,70 (6), 2285-95.

5.Liu, J, Zhou, W, Li, S. S, Sun, Z, Lin, B, Lang, Y.  Y, He, J. Y, Cao, X, Yan, T, Wang,L, Lu, J, Han, Y. H, Cao, Y, Zhang, X. K, Zeng, J. Z, Modulation of orphan  nuclear receptor Nur77-mediated apoptotic pathway by acetylshikonin and  analogues.Cancer Res2008,68 (21), 8871-80.

6.Han, Y. H, Zhou, H, Kim, J. H, Yan, T. D, Lee,  K. H, Wu, H, Lin, F, Lu, N.; Liu, J,

Zeng, J.  Z,Zhang, X. K., A unique cytoplasmic  localization of retinoic acid receptor-gamma and its regulations.J Biol Chem2009, 284 (27), 18503-14.


Tel:+86-592-  2181851 

Fax:+86-592-2181879

E-mail:xkzhang@xmu.edu.cn

Copyright©2011 School of Pharmaceutical Sciences Xiamen University All Rights Reserved